Oncocount RGCC
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning.
The test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount RGCC test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).
Purpose of the test
Purpose of the test
When a tumour appears in the body, scientists have found that cells break off and enter the bloodstream. Known as circulating tumour cells (CTCs), they provide an accurate biomarker that scientists can use to identify cancer.
Oncocount RGCC provides clinicians with two crucial pieces of information: whether CTCs are present in the blood, and what concentration. The presence of CTCs indicates the likelihood of cancer in the body. The more CTCs in the bloodstream, the larger the tumour.
This test should be used as an early-warning test for patients who are concerned that their cancer may be returning. The results, which need to be interpreted by a clinician, can be used as the basis for further investigation.
By detecting cancer early, patients have the best chance of a successful treatment outcome.
Useful information
Useful information
Oncocount RGCC has been assessed for sensitivity and specificity for diagnostic purposes. It should not be used to confirm a diagnosis of cancer but is designed to help monitor a patient’s status during and after treatment and assess the risk of relapse.
The test requires 7-10 ml of whole (peripheral) blood, to be sent in an immobilising liquid in a 10ml volume vial tube. RGCC can provide a sampling kit including a vial tube, and detailed instructions on how to collect and send samples, upon request (see below).
Support and training
Support and training
At RGCC, we provide ongoing training and support for clinicians on how to conduct tests and interpret the results for patients. If you would like more information on how to access, perform or analyse the results of the Oncocount RGCC test, then get in touch today.